Core Laboratories Third Quarter 10-Q

EX-99 7 exhibit-99_5.htm EXHIBIT 99.5 Core Laboratories Third Quarter 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 10-Q

(Mark One)
X	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
	SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2006

OR

	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
	SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ______________

Commission File Number: 001-14273

CORE LABORATORIES N.V.
(Exact name of registrant as specified in its charter)

The Netherlands		Not Applicable
(State of other jurisdiction of		(I.R.S. Employer Identification No.)
incorporation or organization)

Herengracht 424
1017 BZ Amsterdam
The Netherlands		Not Applicable
(Address of principal executive offices)		(Zip Code)

(31-20) 420-3191
(Registrant's telephone number, including area code)

None
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [ X ] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. Large accelerated filer [ X ] Accelerated filer [ ] Non-accelerated filer [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [ X ]

The number of common shares of the Registrant, par value EUR 0.04 per share, outstanding at October 25, 2006 was 25,089,386.

CORE LABORATORIES N.V.
FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2006

INDEX

		Page
PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements

	Consolidated Balance Sheets at September 30, 2006 (Unaudited) and December 31, 2005	1

	Consolidated Statements of Operations (Unaudited) for the Three Months Ended
	September 30, 2006 and 2005	2

	Consolidated Statements of Operations (Unaudited) for the Nine Months Ended
	September 30, 2006 and 2005	3

	Consolidated Statements of Cash Flows (Unaudited) for the Nine Months Ended
	September 30, 2006 and 2005	4

	Notes to (Unaudited) Consolidated Interim Financial Statements	5

Item 2.	Management's Discussion and Analysis of Financial Condition and
	Results of Operations	15

Item 3.	Quantitative and Qualitative Disclosures of Market Risk	22

Item 4.	Controls and Procedures	22


PART II - OTHER INFORMATION

Item 1.	Legal Proceedings	23

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23

Item 5.	Other Information	23

Item 6.	Exhibits	24

	Signature	25

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

CORE LABORATORIES N.V.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

				September 30,	December 31,
				2006	2005
		ASSETS		(Unaudited)
CURRENT ASSETS:
	Cash and cash equivalents			$ 12,456	$ 13,743
	Accounts receivable, net of allowance for doubtful accounts of $4,760 and
	$4,526 at 2006 and 2005, respectively			111,062	99,129
	Inventories, net			31,772	29,104
	Prepaid expenses and other current assets			14,266	11,269
		TOTAL CURRENT ASSETS		169,556	153,245

PROPERTY, PLANT AND EQUIPMENT, net				87,482	81,342
INTANGIBLES, net				6,566	6,720
GOODWILL				132,618	132,618
DEFERRED TAX ASSET				14,665	11,452
OTHER ASSETS				9,983	9,224
		TOTAL ASSETS		$ 420,870	$ 394,601

		LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
	Current maturities of long-term debt and capital lease obligations			$ 181	$ 2,544
	Accounts payable			30,769	32,557
	Accrued payroll and related costs			25,401	17,371
	Taxes other than payroll and income			6,919	5,660
	Income taxes payable			8,485	-
	Unearned revenues			5,567	3,233
	Other accrued expenses			9,189	7,391
	Current liabilities of discontinued operations			-	800
		TOTAL CURRENT LIABILITIES		86,511	69,556

LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS				107,002	86,104
DEFERRED COMPENSATION				9,586	7,585
OTHER LONG-TERM LIABILITIES				25,859	16,034
COMMITMENTS AND CONTINGENCIES
MINORITY INTEREST				1,477	1,065

SHAREHOLDERS' EQUITY:
	Preference shares, EUR 0.04 par value in 2006 and EUR 0.01 par value in 2005;
			3,000,000 shares authorized, none issued or outstanding	-	-
	Common shares, EUR 0.04 par value in 2006 and EUR 0.01 par value in 2005;
			100,000,000 shares authorized, 25,527,327 issued and 25,089,385 outstanding at 2006
			and 26,797,354 issued and 25,774,339 outstanding at 2005	1,446	474
	Additional paid-in capital			18,249	103,832
	Deferred compensation			-	(940)
	Retained earnings			198,937	141,448
	Treasury shares (at cost), 437,942 at 2006 and 1,023,015 at 2005			(28,197)	(30,557)
		TOTAL SHAREHOLDERS' EQUITY		190,435	214,257
		TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		$ 420,870	$ 394,601

The accompanying notes are an integral part of these consolidated financial statements.

CORE LABORATORIES N.V.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

		Three Months Ended September 30,
		2006	2005
		(Unaudited)
REVENUES:
	Services	$ 109,950	$ 90,328
	Product Sales	35,576	29,856
		145,526	120,184
OPERATING EXPENSES:
	Cost of services	74,240	69,737
	Cost of sales	26,282	23,027
	General and administrative expenses	6,250	10,873
	Depreciation	4,423	3,922
	Amortization	94	124
	Other (income), net	447	(1,636)
OPERATING INCOME		33,790	14,137
Interest expense		1,930	1,923
Income before income tax expense		31,860	12,214
Income tax expense		9,476	4,724
NET INCOME		$ 22,384	$ 7,490

EARNINGS PER SHARE INFORMATION:
Basic earnings per share		$ 0.88	$ 0.29

Diluted earnings per share		$ 0.83	$ 0.27

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic		25,304	26,108

Diluted		26,951	28,121

The accompanying notes are an integral part of these consolidated financial statements.

CORE LABORATORIES N.V.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

		Nine Months Ended September 30,
		2006	2005
		(Unaudited)
REVENUES:
	Services	$ 315,423	$ 272,309
	Product Sales	107,455	82,211
		422,878	354,520
OPERATING EXPENSES:
	Cost of services	221,768	207,780
	Cost of sales	79,097	65,568
	General and administrative expenses	25,458	26,180
	Depreciation	12,473	11,976
	Amortization	256	364
	Other (income), net	(2,969)	(1,678)
OPERATING INCOME		86,795	44,330
Interest expense		4,785	6,034
Income before income tax expense		82,010	38,296
Income tax expense		24,521	11,834
NET INCOME		$ 57,489	$ 26,462

EARNINGS PER SHARE INFORMATION:
Basic earnings per share		$ 2.25	$ 1.01

Diluted earnings per share		$ 2.11	$ 0.95

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic		25,551	26,095

Diluted		27,304	27,996

The accompanying notes are an integral part of these consolidated financial statements.

CORE LABORATORIES N.V.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

			Nine Months Ended September 30,
			2006	2005
			(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income			$ 57,489	$ 26,462
Adjustments to reconcile income to net cash provided by operating activities:
	Net provision for doubtful accounts		577	891
	Inventory obsolescence		1,553	2,276
	Equity in loss (income) of affiliates		53	(44)
	Minority interest		151	(159)
	Stock-based compensation		3,611	12,135
	Depreciation and amortization		12,729	12,340
	Debt issuance costs amortization		86	228
	Gain on sale of assets		(782)	(518)
	Gain on involuntary sale of fixed asset		-	(875)
	Gain on insurance recovery		(492)	(534)
	Increase in value of life insurance policies		(132)	(91)
	Deferred income taxes		(5,792)	651
	Changes in assets and liabilities, net of effect of dispositions:
		Accounts receivable	(13,765)	(3,411)
		Inventories	(5,770)	(3,099)
		Prepaid expenses and other current assets	(584)	2,064
		Other assets	(42)	26
		Accounts payable	(1,237)	(1,625)
		Accrued expenses	21,514	3,514
		Other long-term liabilities	10,911	5,552
	Net cash provided by operating activities		80,078	55,783
CASH FLOWS FROM INVESTING ACTIVITIES:
		Capital expenditures	(16,347)	(12,291)
		Patents and other intangibles	(103)	(103)
		Proceeds from sale of assets	2,222	3,422
		Premiums on life insurance	(753)	(475)
	Net cash used in investing activities		(14,981)	(9,447)
CASH FLOWS FROM FINANCING ACTIVITIES:
		Repayment of debt	(23,439)	(31,762)
		Proceeds from debt borrowings	42,000	9,000
		Capital lease obligations	(24)	(182)
		Stock options exercised	13,859	7,012
		Excess tax benefits from stock-based payments	5,671	-
		Debt issuance costs	-	(314)
		Repurchase of common shares	(104,451)	(27,012)
	Net cash used in financing activities		(66,384)	(43,258)
NET CHANGE IN CASH AND CASH EQUIVALENTS			(1,287)	3,078
CASH AND CASH EQUIVALENTS, beginning of period			13,743	16,030
CASH AND CASH EQUIVALENTS, end of period			$ 12,456	$ 19,108

Non-cash investing and financing activities:
	Change in par value of common stock		$ 977	$ -
	Financial capital expenditures		$ 2,350	$ 18
	Common stock issued pursuant to share-based compensation arrangements		$ -	$ 9,104

The accompanying notes are an integral part of these consolidated financial statements.

CORE LABORATORIES N.V.

NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1. BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements include the accounts of Core Laboratories N.V. and its subsidiaries and have been prepared in accordance with generally accepted accounting principles ("GAAP") in the United States of America ("U.S.") for interim financial information using the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information and footnote disclosures required by GAAP for complete financial statements.

Core Laboratories N.V. uses the equity method of accounting for all investments in which it has less than a majority interest and over which it does not exercise control. Minority interest has been recorded to reflect outside ownership attributable to consolidated subsidiaries that are less than 100% owned. In the opinion of management, all adjustments considered necessary for a fair presentation have been included in these financial statements. Furthermore, the operating results presented for the nine months ended September 30, 2006 may not necessarily be indicative of the results that may be expected for the year ending December 31, 2006.

Core Laboratories N.V.'s balance sheet information for the year ended December 31, 2005 was derived from the 2005 audited consolidated financial statements but does not include all disclosures in accordance with GAAP. Certain reclassifications have been made to year 2005 amounts in order to present these results on a comparable basis with amounts for year 2006.

References to "Core Lab", "we", "our", and similar phrases are used throughout this Quarterly Report on Form 10-Q and relate collectively to Core Laboratories N.V. and its consolidated affiliates.

These financial statements should be read in conjunction with the financial statements and the summary of significant accounting policies and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2005.

2. INVENTORIES

Inventories consist of the following (in thousands):

	September 30,	December 31,
	2006	2005
	(Unaudited)
Finished goods	$ 25,914	$ 22,896
Parts and materials	7,812	7,381
Work in progress	1,019	1,183
Total inventories	34,745	31,460
Less - valuation reserves	2,973	2,356
Inventories, net	$ 31,772	$ 29,104

We include freight costs incurred for shipping inventory to customers in the Cost of Sales line of the Consolidated Statement of Operations.

3. GOODWILL AND INTANGIBLES

We account for intangible assets with indefinite lives, including goodwill, in accordance with Statement of Financial Accounting Standards No. 142, "Goodwill and Other Intangible Assets", which requires us to evaluate these assets for impairment annually, or more frequently if an indication of impairment has occurred. Based upon our most recent evaluation, management determined that goodwill was not impaired. We amortize intangible assets with a defined term on a straight-line basis over their respective useful lives. There were no significant changes related to our intangible assets for the nine months ended September 30, 2006. The composition of goodwill by business segment at September 30, 2006 is consistent with the amounts disclosed in our Annual Report on Form 10-K as of December 31, 2005.

4. DEBT AND CAPITAL LEASE OBLIGATIONS

Debt is summarized in the following table (in thousands):

	September 30,	December 31,
	2006	2005
	(Unaudited)
Credit Facility	$ 107,000	$ 86,000
Capital lease obligations	11	36
Other indebtedness	172	2,612
Total debt and capital leases obligations	107,183	88,648
Less - short-term debt included in other indebtedness	72	2,412
Less - current maturities of long-term debt and capital lease obligations	109	132
Long-term debt and capital lease obligations	$ 107,002	$ 86,104

We maintain a revolving credit facility ("Credit Facility") allowing for an aggregate borrowing capacity of $125.0 million. The maturity date of the Credit Facility is December 20, 2010. As amended, this agreement provides an option to increase the commitment under the Credit Facility to $175.0 million, if certain conditions are met. Our available borrowing capacity was reduced by outstanding letters of credit and performance guarantees and bonds totaling $6.3 million at September 30, 2006 related to certain projects in progress. Available capacity under the Credit Facility was $11.7 million as of September 30, 2006. The Credit Facility requires interest payments to be made based on the interest period selected. At September 30, 2006, the weighted average interest rate of amounts outstanding under the Credit Facility was 6.08%, and the weighted average interest rate for the nine months ended September 30, 2006 under this facility was 5.93%.

5. PENSIONS AND OTHER POSTRETIREMENT BENEFITS

We provide a noncontributory defined benefit pension plan covering substantially all of our Dutch employees based on years of service and final pay or career average pay, depending on when the employee began participating. Employees are immediately vested in the benefits earned. We fund the future obligations of this plan by purchasing investment contracts from a large national insurance company. We make annual premium payments, based upon each employee's age and current salary, to the insurance company.

The following table summarizes the components of net periodic pension cost under this plan for the three and nine months ended September 30, 2006 and 2005 (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,
	2006	2005	2006	2005
	(Unaudited)		(Unaudited)
Service cost	$ 295	$ 166	$ 905	$ 523
Interest cost	221	195	678	613
Expected return on plan assets	(214)	(221)	(657)	(695)
Unrecognized pension asset	(20)	(21)	(62)	(71)
Unrecognized pension obligation	54	-	167	-
Net periodic pension cost	$ 336	$ 119	$ 1,031	$ 370

During the nine months ended September 30, 2006, we contributed approximately $1.2 million, as determined by the insurance company, to fund the estimated 2006 premiums on investment contracts held by the plan.

6. COMMITMENTS AND CONTINGENCIES

Executive Employment Agreements

In 1998, we entered into employment agreements with our four senior executive officers that provided for severance benefits. The present value of the long-term liability for the benefits due upon severing the employment of these employees is approximately $2.2 million at September 30, 2006.

Legal Proceedings

From time to time, we may be subject to legal proceedings and claims that arise in the ordinary course of business. We believe that the resolution of all litigation currently pending or threatened against it or any of its subsidiaries should not have a material adverse effect on its consolidated financial condition, results of operations or liquidity; however, because of the inherent uncertainty of litigation, we cannot provide assurance that the resolution of any particular claim or proceeding to which it or any of its subsidiaries is a party will not have a material adverse effect on its consolidated results of operations or liquidity for the period in which that resolution occurs.

7. SHAREHOLDERS' EQUITY

During the three and nine months ended September 30, 2006, we repurchased 414,842 of our common shares for $26.8 million, at an average price of $64.68 per share, and 1,891,924 of our common shares for $104.5 million, at an average price of $55.21 per share. In January 2006, 42,015 shares valued at $1.8 million, or $42.98 per share, and in May 2006, 195,467 shares valued at $12.4 million, or $63.60 per share, were acquired pursuant to the terms of a stock-based compensation plan, in settlement by the participants of personal tax burdens that may result from the issuance of common shares under this arrangement.

For the three and nine months ended September 30, 2006, we issued 100,068 and 942,570 of our common shares, associated with stock option exercises for which we received proceeds of approximately $1.6 million and $13.9 million.

At our Annual Shareholders' Meeting on June 28, 2006 (the "Meeting"), our shareholders approved the cancellation of all of the 2,476,997 treasury shares we had repurchased up to the date of the Meeting. These 2,476,997 treasury shares were cancelled in June 2006 at historical cost, totaling $106.8 million, or $43.12 per share, resulting in a decrease in treasury shares at cost and a corresponding decrease in additional paid-in-capital and common stock. Our shareholders also approved the extension of the authority of our Management Board to repurchase up to 10% of the Company's outstanding share capital up through December 28, 2007. At September 30, 2006, we had the authority to repurchase up to 2,104,184 additional shares under our stock repurchase program.

8. EARNINGS PER SHARE

We compute basic earnings per common share by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per common and potential common shares include additional shares in the weighted average share calculations associated with the incremental effect of dilutive employee stock options, restricted stock awards and contingently issuable shares, as determined using the treasury stock method. The following table summarizes the calculation of weighted average common shares outstanding used in the computation of diluted earnings per share (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,
	2006	2005	2006	2005
	(Unaudited)		(Unaudited)
Weighted average basic common shares outstanding	25,304	26,108	25,551	26,095
Effect of dilutive securities:
Stock options ⁽¹⁾	1,421	1,540	1,498	1,515
Contingent shares	159	245	146	256
Restricted stock and other	67	228	109	130
Weighted average diluted common and potential common shares outstanding	26,951	28,121	27,304	27,996

______________________

(1) The effect of anti-dilutive shares associated with these securities has been excluded from the diluted weighted average share calculations at September 30, 2006 and 2005. If these shares had been included, the impact would have been a decrease in weighted average shares outstanding of 0 shares for the three and nine months ended September 30, 2006, respectively and 1 and 6 shares for the three and nine months ended September 30, 2005, respectively.

9. STOCK-BASED COMPENSATION

We have granted stock options and restricted stock awards under two stock option plans: the 1995 Long-Term Incentive Plan (the "Plan") and the 2006 Nonemployee Director Stock Incentive Plan (the "Director Plan"). Restricted shares issued under the Plan include the Executive Restricted Share Matching Program ("ESMP"), the Performance Share Award Program ("PSAP") and the Restricted Share Award Program ("RSAP").

Effective January 1, 2006, we adopted Statement of Financial Accounting Standard No. 123R, "Share-Based Payment" ("SFAS 123R") SFAS 123R using the modified prospective transition method. Under that transition method, compensation expense that we recognized for the three and nine months ended September 30, 2006 included: (a) compensation expense for all stock-based payments granted prior to, but not yet vested as of, January 1, 2006, based on the grant date fair value estimated in accordance with the original provisions of SFAS 123, "Accounting for Stock-Based Compensation", and (b) compensation expense for all stock-based payments granted on or after January 1, 2006, based on the grant date fair value estimated in accordance with the provisions of SFAS 123R. Results from prior periods have not been restated. This statement requires compensation costs related to share-based payments, including stock options, to be recognized in the Consolidated Statement of Operations based on their fair values. The expense is recognized over the requisite service period of the award. We previously recognized expense for stock-based compensation arrangements in accordance with the provisions of Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees", and related interpretations ("APB 25"). Accordingly, compensation expense was recognized for the excess, if any, of the stock price on the grant date over the option exercise price. No compensation expense was recorded under APB 25 for awards granted under our employee stock option plan as all options issued had exercise prices at least equal to the fair value of the stock on the grant date. The pro forma effects upon net income and earnings per share for stock options are disclosed below per SFAS Statement No. 123, "Accounting for Stock-Based Compensation."

As a result of adopting SFAS 123R, we included approximately $1.0 million and $3.6 million of stock-based compensation expense in the Consolidated Statements of Operations for the three and nine month period ended September 30, 2006, respectively. The effect on net income and earnings per share if we had applied the fair value recognition provisions of SFAS 123R to stock-based employee compensation in the prior year comparable period is as follows (in thousands):

	Three Months Ended	Nine Months Ended
	September 30, 2005	September 30, 2005
	(Unaudited)
Net income (loss) as reported:	$ 7,490	$ 26,462
Add: stock-based compensation expense included in reported income, net of tax	3,841	5,270
Less: stock-based compensation expense determined under fair value method, net of tax	(4,250)	(6,443)
Pro forma income (loss)	$ 7,081	$ 25,289
Basic earnings (loss) per share:
As reported	$ 0.29	$ 1.01
Pro forma	$ 0.27	$ 0.97
Diluted earnings (loss) per share:
As reported	$ 0.27	$ 0.95
Pro forma	$ 0.25	$ 0.90

Prior to the adoption of SFAS 123R, we presented deferred compensation as a separate component of shareholders' equity. In accordance with provisions of SFAS 123R, on January 1, 2006 we reclassified the balance in deferred compensation to Additional Paid-In Capital on our Consolidated Balance Sheet.

Prior to the adoption of SFAS 123R, we presented all tax benefits for deductions resulting from the exercise of stock options as operating cash flows in our Consolidated Statement of Cash Flows. SFAS 123R requires the cash flows resulting from the tax benefits for tax deductions in excess of the compensation expense recorded for those options to be classified as financing cash flows.

For the three and nine months ended September 30, 2006, stock-based compensation expense recognized in the income statement is as follows (in thousands):

	Three Months Ended September 30,	Nine Months Ended September 30,
	2006	2006
	(Unaudited)
Cost of sales and services	$ 331	$ 1,140
General and administrative	710	2,460
Total stock-based compensation expense	$ 1,041	$ 3,600

Stock Options

The Plan, as amended, provided for a maximum of 5,400,000 common shares to be granted to eligible employees. Awards under this plan are provided to encourage stock ownership by corporate and divisional management, as we believe that widespread common share ownership by key employees is an important means of encouraging superior performance and retaining employees. Stock options that have been granted under this plan have historically been granted at market value on the date of grant, are exercisable for a period of 10 years and vest in equal installments over four years. Common share options were, and restricted stock award grants are, considered annually based on competitive multiples of base salary. Senior executives typically have a higher multiple and, as such, have a greater portion of their total compensation linked to our long-term success. In determining the appropriate grant multiples, we target the market median among publicly held oilfield service companies of similar size. At September 30, 2006, approximately 77,700 shares were available for future issuance under the Plan. No stock options have been granted during 2006 under the Plan.

On June 28, 2006, the 1995 Nonemployee Director Stock Option Plan, which provides common shares for grant to our eligible Supervisory Directors, was amended, restated and renamed as the 2006 Nonemployee Director Stock Incentive Plan. The primary change effected by the 2006 amendment was to eliminate the automatic, formula grant of stock options under the Director Plan and to replace that formula approach with the discretionary right of the Supervisory Board to grant stock options, restricted shares, or any combination thereof. Under the Director Plan, each nonemployee Supervisory Director is generally granted 2,000 performance restricted shares (4,000 shares if such nonemployee Supervisory Director is the Chairman) that will vest at the end of a three-year measurement period subject to our performance as measured against certain predetermined metrics each year generally on the first date in the calendar year set by the Supervisory Board for the issuance of equity-based awards to more than 10 employees under our Plan. Only nonemployee Supervisory Directors are eligible for these equity-based awards. As of September 30, 2006, approximately 80,000 shares were available for issuance under the Director Plan. Although restricted shares have been granted in 2006 in accordance with the above, no stock options have been granted during 2006 under the Director Plan.

In December 2005, we accelerated the vesting of all outstanding unvested options. Prior to the modification, there were 322,072 stock options that were unvested, which represented less than 12% of the total stock options that were outstanding. The options were vested in anticipation of the adoption of SFAS No. 123R as the Option Subcommittee determined that the administrative costs of applying the provisions of SFAS No. 123R to the few remaining unvested options far exceeded the benefit of allowing these options to vest as originally scheduled under the plans. As a result of the modification, we determined that the increase in the intrinsic value of the unvested options over the original grant price was approximately $7.9 million. Due to the accelerated vesting, we recorded $0.1 million in non-cash compensation charge which is related to the excess of the intrinsic value over the fair market value of the our stock on the acceleration date of those options that would have been forfeited or expired unexercised had the vesting not been accelerated. In determining the forfeiture rates of the stock options, we reviewed the unvested options' original life, time remaining to vest and whether these options were held by our officers and directors. The compensation charge is adjusted in future period financial results as actual forfeitures are realized. For the nine months ended September 30, 2006, there were no material changes in actual forfeitures from estimates.

The following table presents the change in outstanding stock options issued under the Plan and the Director Plan for the nine months ended September 30, 2006:

	Options Outstanding	Range of Exercise Prices	Weighted Average Exercise Price	Aggregate Intrinsic Value
Balance as of December 31, 2005	2,735,159	$ 0.01 - 61.19	$ 13.48	$ 50.32
Options granted	-	-	-	-
Options exercised	(942,570)	8.38 - 61.19	14.70	49.10
Options canceled	(62,746)	8.40 - 23.00	16.10	47.70
Balance as of September 30, 2006	1,729,843	$ 0.01 - 25.00	$ 12.72	$ 51.08

Exercisable	1,729,843	$ 0.01 - 25.00	$ 12.72	$ 51.08

The aggregate intrinsic value in the table represents the total pretax intrinsic value (the difference between our closing stock price on the last trading day of the quarter and the exercise price) that would have been received by the option holders had all option holders exercised their options on September 30, 2006.

For the three and nine months ended September 30, 2006, cash received from the exercise of stock options was $1.6 million and $13.9 million, respectively.

The following table summarizes stock options outstanding and exercisable as of September 30, 2006 by exercise price range:

	Options Outstanding/ Exercisable	Weighted Average Remaining Life	Weighted Average Exercise Price
Range of Exercise Prices:
$0.01	41,465	3.3	$ 0.01
$7.09 to $11.15	838,896	6.2	9.48
$13.06 to $16.10	521,238	4.5	14.89
$18.38 to $23.00	324,244	3.5	19.05
$25.00	4,000	9.2	25.00
	1,729,843	5.1	$ 12.72

Executive Restricted Share Matching Program

The ESMP was implemented in June 2002 to encourage personal investment in our common stock by our executive officers. Under the program, we matched on a one-for-one basis each share that an executive purchased on the open market or held in his deferred compensation, 401(k) or other retirement account as of June 1, 2002, up to a maximum of 50,000 shares per participant.

Pursuant to the ESMP, on June 1, 2005, we issued an additional 76,200 restricted shares (the "Restricted Gross-Up Shares") in the aggregate to the participants to reimburse them for tax liabilities resulting from the vesting of the original grant in June 2005 of 132,853 restricted shares under the ESMP and their eventual vesting in the Restricted Gross-Up Shares. In order to vest in the Restricted Gross-Up Shares, a participant generally must remain in our employment until June 1, 2007, and maintain continuous ownership until such date of (a) the equivalent number of shares the participant initially purchased in order to receive the original restricted matching share award plus (b) a number of the shares received in the restricted matching share award (which number of shares is generally equal to all of the shares included in the restricted matching share award less a percentage of such shares surrendered by the participant to pay applicable taxes upon their vesting). A participant may become vested in some or all of the Restricted Gross-Up Shares prior to June 1, 2007, in the event of a change in control or the termination of the participant's employment by reason of death, disability, an involuntary termination without cause, or after attaining the age of 60 and completing 10 years of employment with us.

Upon adoption of SFAS 123R, the Restricted Gross-Up Shares were classified as an equity award as a result of the service condition. Historically, we had accounted for the Restricted Gross Up Shares under APB 25 as a variable award and remeasured it at each balance sheet date. Effective January 1, 2006, the fair value of the Restricted Gross Up Shares is fixed at the original grant-date fair value with compensation recorded over the vesting period based on the estimated number of shares that management believes will ultimately vest. During the nine months ended September 30, 2006, we recorded approximately $0.7 million of compensation expense for the Restricted Gross-Up Shares. As of September 30, 2006, approximately 33% of the Restricted Gross-Up Shares remain unvested, assuming that all the awards will ultimately vest, resulting in approximately $0.7 million of compensation expense to be recognized through the ultimate vesting date of June 1, 2007.

Performance Share Award Program

Awards Under the Plan

Under the PSAP, certain executives were awarded rights to receive a pre-determined number of common shares if certain performance targets are met, as defined in the applicable agreements for the respective three-year performance period. Rights relating to an aggregate of 125,000 shares ("Tranche 2"), 120,000 shares ("Tranche 3"), and 120,000 shares ("Tranche 4") were issued with respect to the performance periods ending on December 31, 2005, 2006, and 2007, respectively. Unless there is a change in control, as defined in the PSAP, none of these awards will vest if the specified performance targets are not met as of the last day of the respective performance periods.

To meet the performance targets under Tranche 2, our common shares had to perform as well as or better than the 50th percentile of the return earned by the common stock of the companies comprising the Philadelphia Oil Services Sector Index ("OSX") for the applicable performance period. If our common shares performed as well as or better than the 50th percentile but below the 75th percentile of the companies comprising the OSX, then the number of rights eligible to vest would have been interpolated between 20% and 100% of the shares granted. If our common shares performed as well as or better than the 75th percentile of the companies comprising the OSX, then 100% of the rights would have been eligible to vest.

The performance targets for Tranche 3 are similar to those for Tranche 2 for rights relating to 60,000 shares. Rights related to the other 60,000 shares granted under Tranche 3 will be eligible to vest if our calculated return on equity ("ROE"), as defined in the PSAP, equals or exceeds a pre-determined target return on equity of 18%. Pursuant to the agreement, return on equity is calculated by dividing earnings before interest and income tax for the performance period by ending shareholders' equity for the performance period. Unless there is a change in control, none of these 60,000 shares will be issued if our return on equity does not equal or exceed 12% for the three-year performance period ending December 31, 2006. If our return on equity for the performance period equals 12%, then 20% of the shares will be issued, and if our return on equity equals or exceeds 18%, then 100% of the shares will be issued. If our return on equity for the performance period is greater than 12% but less than 18%, then the number of shares to be issued would be interpolated based on the terms of the agreement. If a change in control occurs prior to the last day of the performance period and while the executive officer is employed by us, then all of the executive officer's performance shares will vest as of the date of the change in control.

The performance target for Tranche 4, for which the performance period began on January 1, 2005 and ends on December 31, 2007, is based on a calculated ROE similar to the terms for Tranche 3 discussed above, except that the pre-determined target ROE is 24%. Unless there is a change in control, none of these 120,000 shares will be issued if our ROE is less than 20% for the three-year performance period. If our ROE for the performance period equals 20%, then 50% of the shares will be issued, and if our ROE for the performance period equals or exceeds 24%, then 100% of the shares will be issued. If our ROE for the performance period is greater than 20% but less than 24%, then the number of shares to be issued would be interpolated based on the terms of the agreement.

Awards Under the Director Plan

On September 15, 2006, we issued rights relating to an aggregate of 12,000 shares under the Director Plan to our non employee Supervisory Directors for which the performance period began on September 15, 2006 and ends on September 15, 2009, ("Director Tranche 1"). The performance target for Director Tranche 1 is based on a calculated ROE, as defined in the Director Tranche 1 agreement, that equals or exceeds the pre-determined target ROE of 35%. Unless there is a change in control, none of these 12,000 shares will be issued if our ROE is less than 28% for the three-year performance period. If our ROE for the performance period equals 28%, then 20% of the shares will be issued, and if our ROE for the performance period equals or exceeds 35%, then 100% of the shares will be issued. If our ROE for the performance period is greater than 28% but less than 35%, then the number of shares to be issued would be interpolated based on the terms of the agreement. This arrangement is an equity award under SFAS 123R that will require us to recognize compensation expense totaling $0.8 million over a three-year period that began on September 15, 2006.

Upon adoption of SFAS 123R, all of the PSAP shares were classified as equity awards. The performance targets for Tranche 2 and half of Tranche 3 associated with the OSX are considered to be a market condition, while the performance targets for the other half of Tranche 3 and all of Tranche 4 are considered to be a performance condition. Historically, we had accounted for these instruments under APB 25 as variable awards and remeasured them at each balance sheet date. Effective January 1, 2006, the fair value of the awards are fixed at the original grant-date fair value with compensation recorded over the vesting period based on the estimated number of awards that management believes will ultimately vest.

In January 2006, the Options Subcommittee of our Board of Supervisory Directors determined that the performance target criteria had been met relating to an aggregate of 125,000 shares under Tranche 2 and we issued these 125,000 common shares on January 17, 2006. The intrinsic value of the award was approximately $5.4 million, which had been recorded as stock-based compensation through December 31, 2005. Simultaneously, we repurchased 42,015 of these common shares from the participants at the closing market price on that day to settle personal tax liabilities which may result from the issuance of these shares, as permitted by the agreement. We recorded these repurchased shares as treasury stock with an aggregate cost of $1.8 million, at $42.98 per share. Accordingly, at September 30, 2006, there remains outstanding rights with respect to 120,000 shares under Tranche 3, rights with respect to 118,000 shares under Tranche 4, and rights with respect to 12,000 shares under Director Tranche 1, which may vest at December 31, 2006, December 31, 2007, and September 15, 2009, respectively. The total compensation related to the nonvested portion of Tranche 3, Tranche 4 and Director Tranche 1 is approximately $0.2 million, $1.1 million and $0.8 million, respectively. The weighted average period over which this compensation will be recognized is 15 months. We included $0.2 million of compensation expense for each of Tranche 3 and Tranche 4 and $11,000 of compensation expense for Director Tranche 1 in our results of operations for the three months ended September 30, 2006.

For diluted weighted average shares outstanding, based on our common stock's performance relative to the OSX and our ROE, using the treasury stock method, we calculated 159,129 and 146,114 contingently issuable PSAP shares for the three and nine month period ending September 30, 2006, respectively. See Note 8, Earnings Per Share.

Restricted Share Award Program

The Options Subcommittee of our Board of Supervisory Directors has previously approved the RSAP to continue to attract and retain the best employees, and to better align employee interests with those of our shareholders. Under this arrangement, in 2005, we granted to key employees an aggregate of 142,600 restricted shares of our common stock under the RSAP at a grant date fair value of $26.80. This arrangement is a fixed award which would have required us to recognize compensation expense totaling $3.8 million over a seven-year vesting period that began on January 1, 2005. This award also contained two performance accelerators either of which, if satisfied, or if certain other events occured as specified in the related agreements, may have required earlier recognition of this expense. The first performance accelerator required that our average closing stock price attain a level equal to or above $28 per share over a period of 20 consecutive trading days ending within the period beginning on the 21st trading day after April 1, 2006 and ending on April 1, 2008. The second performance accelerator required the average closing stock price to attain a level equal to or above $32 per share over a period of 20 consecutive trading days ending within the period beginning on the first trading day after April 1, 2008 and ending April 1, 2010. Upon adoption of SFAS 123R, the RSAP was classified as an equity award. The RSAP was originally recorded at the grant-date fair value and was being amortized over the expected life of the award. On May 1, 2006 the first performance accelerator was met and 139,400 shares vested with approximately $0.2 million and $0.9 million of compensation expense being recorded for the three and nine months ended September 30, 2006, respectively. Simultaneously, we repurchased 38,748 of these common shares from the participants at the closing market price on that day to settle personal tax liabilities which may result from the vesting of these shares, as permitted by the agreement. We recorded these repurchased shares as treasury stock with an aggregate cost of $2.4 million, or $63.20 per share.

In May 2006, the Options Subcommittee of the Board of Supervisory Directors approved a grant of 163,500 restricted shares to key employees under the RSAP program. These shares vest in the amount of 1/6th of each grant on each of the six annual anniversaries following the date of grant; provided, however, that full vesting will occur if an employee's employment is terminated by reason of death or disability or if an employee continues in our employment until the date upon which a change of control occurs. Similar to the grant discussed previously, this arrangement is an equity award under SFAS 123R that will require us to recognize compensation expense totaling $8.3 million over a six-year vesting period that began on May 15, 2006. We recorded compensation expense totaling $0.4 million and $0.6 million under this arrangement for the three and nine months ended September 30, 2006. The estimate of future compensation expense includes a 2% forfeiture rate which was derived from historical actual forfeitures by employees that have typically been granted such awards adjusted for management's expectations of future forfeitures.

Nonvested restricted stock awards as of September 30, 2006 and changes during the nine months ended September 30, 2006 were as follows:

	Number of Shares	Weighted Average Grant Date Fair Value
Nonvested at December 31, 2005	502,400	$ 21.08
Granted	175,500	57.83
Vested	264,400	19.58
Forfeited	4,800	57.36
Nonvested at September 30, 2006	408,700	$ 37.41

We have not issued shares out of treasury stock upon the exercise of options or lapsing of vesting restrictions on restricted stock.

10. OTHER (INCOME)

The components of other (income), net, were as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,
	2006	2005	2006	2005
	(Unaudited)		(Unaudited)
Minority interest	$ 77	$ (263)	$ 151	$ (159)
Loss (gain) on sale of assets	(76)	(614)	(782)	(518)
Foreign exchange (gain) loss	430	(142)	(1,032)	1,428
Interest income	(54)	(238)	(161)	(371)
Gain on involuntary sale of asset	-	-	-	(875)
Gain on insurance recovery	-	-	(492)	(534)
Other	70	(379)	(653)	(649)
Total other (income), net	$ 447	$ (1,636)	$(2,969)	$(1,678)

During the first quarter of 2005, a building at our manufacturing plant in Godley, Texas, was damaged by fire, resulting in the loss of the building, some inventory, as well as other business equipment and supplies. The final settlement was reached in the first quarter of 2006, which resulted in a gain of $0.5 million in excess of the gain recorded in 2005.

Foreign exchange (gains) losses by currency are summarized in the following table (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,
	2006	2005	2006	2005
	(Unaudited)		(Unaudited)
British Pound	$ 5	$ 53	$ (48)	$ 204
Canadian Dollar	44	(288)	(336)	(79)
Euro	(16)	(38)	(270)	282
Russian Ruble	172	(29)	(290)	181
Venezuelan Bolivar	6	32	21	399
Other currencies	219	128	(109)	441
Total (gain) loss	$ 430	$ (142)	$ (1,032)	$ 1,428

11. SEGMENT REPORTING

Our business units have been aggregated into three complementary segments, which provide products and services for improving reservoir performance and increasing oil and gas recovery from new and existing fields.

*	Reservoir Description: Encompasses the characterization of petroleum reservoir rock, fluid and gas samples. We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.

*	Production Enhancement: Includes products and services relating to reservoir well completions, perforations, stimulations and production. We provide integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.

*	Reservoir Management: Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs.

Segment Analysis

We manage each of our business segments separately to reflect the different services and technologies provided and required by each segment. We use the same accounting policies to account for our business segments as those used to prepare our Consolidated Balance Sheets and Consolidated Statements of Operations. We evaluate the performance of our business segments on the basis of operating income.

Summarized financial information related to our business segments is shown in the following tables (in thousands):

	(Unaudited)	Reservoir Description	Production Enhancement	Reservoir Management	Corporate & Other ¹	Consolidated
Three Months Ended September 30, 2006
	Revenues from unaffiliated customers	$ 81,090	$ 55,113	$ 9,323	$ -	$ 145,526
	Inter-segment revenues	24	194	21	(239)	-
	Segment operating income	17,646	13,841	2,086	217	33,790
	Total assets	210,604	159,276	16,387	34,603	420,870
	Capital expenditures	3,929	1,247	81	3,582	8,839
	Depreciation and amortization	2,306	1,231	119	861	4,517

Three Months Ended September 30, 2005
	Revenues from unaffiliated customers	69,189	44,611	6,384	-	120,184
	Inter-segment revenues	190	(178)	-	(12)	-
	Segment operating income (loss)	9,495	7,642	953	(3,953)	14,137
	Total assets	201,128	150,555	15,044	29,313	396,040
	Capital expenditures	1,892	1,413	155	231	3,691
	Depreciation and amortization	2,294	1,051	120	581	4,046

Nine Months Ended September 30, 2006
	Revenues from unaffiliated customers	232,436	162,826	27,616	-	422,878
	Inter-segment revenues	263	526	27	(816)	-
	Segment operating income (loss)	41,098	39,434	6,658	(395)	86,795
	Total assets	210,604	159,276	16,387	34,603	420,870
	Capital expenditures	10,319	4,165	408	3,805	18,697
	Depreciation and amortization	6,785	3,631	341	1,972	12,729

Nine Months Ended September 30, 2005
	Revenues from unaffiliated customers	208,307	127,809	18,404	-	354,520
	Inter-segment revenues	428	97	82	(607)	-
	Segment operating income (loss)	24,606	20,929	2,764	(3,969)	44,330
	Total assets	201,128	150,555	15,044	29,313	396,040
	Capital expenditures	5,369	5,439	432	1,051	12,291
	Depreciation and amortization	7,371	2,953	364	1,652	12,340

	(1) "Corporate & Other" represents those items that are not directly related to a particular segment and eliminations.

12. RECENT ACCOUNTING PRONOUNCEMENTS

In September 2006, the Financial Accounting Standards Board ("FASB") issued FASB Statement No. 158 ("FAS 158"), Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans, An Amendment of FASB Statements No. 87, 88, 106, and 132(R), which addresses the funding status of our defined benefit postretirement plans and may require us to recognize a net liability or asset on our balance sheet starting as of December 31, 2006. FAS 158 will become effective for financial statements issued for fiscal years ending after December 15, 2006. We will adopt this standard as of December 31, 2006. We are currently evaluating the impact of adopting FAS 158 on our financial statements however we do not expect this pronouncement to have a material impact on our financial position and results of operations.

In July 2006, the FASB issued FASB Interpretation No. 48 ("FIN 48"), Accounting for Uncertainty in Income Taxes-An Interpretation of FASB Statement No. 109, which clarifies the accounting for uncertainty in tax positions. FIN 48 requires that we recognize in our financial statements, the impact of a tax position, if that position is more likely than not to be sustainable on audit, based on the technical merits of the position. The provisions of FIN 48 are effective for fiscal years beginning after December 15, 2006, with the cumulative effect of the change in accounting principle recorded as an adjustment to our 2007 fiscal year opening retained earnings. We will adopt this standard the first quarter of 2007. We are currently evaluating the impact of adopting FIN 48 on our financial statements.

13. CONDENSED CONSOLIDATING FINANCIAL INFORMATION

Core Laboratories L.P., a wholly-owned subsidiary of Core Laboratories N.V., is offering $250 million of convertible debt securities which will be fully and unconditionally guaranteed by Core Laboratories N.V.

The following condensed consolidating financial information is included so that separate financial statements of Core Laboratories L.P. are not required to be filed with the U.S. Securities and Exchange Commission. The condensed consolidating financial statements present investments in both consolidated and unconsolidated affiliates using the equity method of accounting.

The following condensed consolidating financial information presents: condensed consolidating balance sheets as of September 30, 2006 and December 31, 2005, statements of income for three and nine month periods ended September 30, 2006 and 2005 and the consolidating statements of cash flows for the nine-month periods ended September 30, 2006 and 2005 of (a) Core Laboratories N.V., parent/guarantor, (b) Core Laboratories L.P., issuer of public debt securities guaranteed by Core Laboratories N.V. and (c) the non-guarantor subsidiaries, (d) consolidating adjustments necessary to consolidate Core Laboratories N.V. and its subsidiaries and (e) Core Laboratories N.V. on a consolidated basis.

Condensed Consolidating Balance Sheets

			September 30, 2006
			Core		Other
		(In thousands)	Laboratories N.V.	Core	Subsidiaries
			(Parent/	Laboratories L.P.	(Non-	Consolidating	Consolidated
			Guarantor)	(Issuer)	Guarantors)	Adjustments	Total
		ASSETS
CURRENT ASSETS:
	Cash and cash equivalents		$ 916	$ (799)	$ 12,339	$ -	$ 12,456
	Accounts receivable, net		266	19,400	91,396	-	111,062
	Inventories, net		-	1,908	29,864	-	31,772
	Prepaid expenses and other current assets		1,189	1,785	11,292	-	14,266
		TOTAL CURRENT ASSETS	2,371	22,294	144,891	-	169,556

PROPERTY, PLANT AND EQUIPMENT, net			-	21,133	66,349	-	87,482
GOODWILL AND INTANGIBLES, net			46,985	2,016	90,183	-	139,184
INTERCOMPANY RECEIVABLES			6,815	123,051	427,196	(557,062)	-
INVESTMENT IN AFFILIATES			394,663	-	500,385	(894,088)	960
DEFERRED TAX ASSET			18,228	977	8,236	(12,776)	14,665
OTHER ASSETS			3,218	2,844	2,961	-	9,023
		TOTAL ASSETS	$ 472,280	$ 172,315	$ 1,240,201	$ (1,463,926)	$ 420,870

		LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
	Current maturities of long-term debt and capital lease obligations		$ 73	$ 100	$ 8	$ -	$ 181
	Accounts payable		64	4,831	25,874	-	30,769
	Other accrued expenses		2,822	15,006	37,733	-	55,561
		TOTAL CURRENT LIABILITIES	2,959	19,937	63,615	-	86,511

LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS			20,000	87,000	2	-	107,002
DEFERRED COMPENSATION			5,318	4,032	236	-	9,586
DEFERRED TAX LIABILITY			-	1,143	11,633	(12,776)	-
OTHER LONG-TERM LIABILITIES			10,676	8,389	6,794	-	25,859
INTERCOMPANY PAYABLES			242,892	41,781	272,389	(557,062)	-

MINORITY INTEREST			-	-	1,477	-	1,477

TOTAL SHAREHOLDERS' EQUITY			190,435	10,033	884,055	(894,088)	190,435
		TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 472,280	$ 172,315	$ 1,240,201	$ (1,463,926)	$ 420,870

Condensed Consolidating Balance Sheets

			December 31, 2005
			Core		Other
		(In thousands)	Laboratories N.V.	Core	Subsidiaries
			(Parent/	Laboratories L.P.	(Non-	Consolidating	Consolidated
			Guarantor)	(Issuer)	Guarantors)	Adjustments	Total
		ASSETS
CURRENT ASSETS:
	Cash and cash equivalents		$ 1,352	$ (243)	$ 12,634	$ -	$ 13,743
	Accounts receivable, net		707	17,148	81,274	-	99,129
	Inventories, net		-	1,336	27,768	-	29,104
	Prepaid expenses and other current assets		427	1,682	9,160	-	11,269
		TOTAL CURRENT ASSETS	2,486	19,923	130,836	-	153,245

PROPERTY, PLANT AND EQUIPMENT, net			219	21,766	59,357	-	81,342
GOODWILL AND INTANGIBLES, net			46,986	2,117	90,235	-	139,338
INTERCOMPANY RECEIVABLES			10,752	68,955	323,781	(403,488)	-
INVESTMENT IN AFFILIATES			289,653	-	526,586	(815,098)	1,141
DEFERRED TAX ASSET			18,228	5,645	664	(13,085)	11,452
OTHER ASSETS			3,026	2,421	2,636	-	8,083
		TOTAL ASSETS	$ 371,350	$ 120,827	$ 1,134,095	$ (1,231,671)	$ 394,601

		LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
	Current maturities of long-term debt and capital lease obligations		$ 2,412	$ 100	$ 32	$ -	$ 2,544
	Accounts payable		743	5,841	25,973	-	32,557
	Other accrued expenses		2,928	10,942	19,785	-	33,655
	Current liabilities of discontinued operations		-	-	800	-	800
		TOTAL CURRENT LIABILITIES	6,083	16,883	46,590	-	69,556

LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS			17,000	69,100	4	-	86,104
DEFERRED COMPENSATION			4,844	2,598	143	-	7,585
DEFERRED TAX LIABILITY			-	-	13,085	(13,085)	-
OTHER LONG-TERM LIABILITIES			8,475	4,742	2,817	-	16,034
INTERCOMPANY PAYABLES			120,691	27,887	254,910	(403,488)	-

MINORITY INTEREST			-	-	1,065	-	1,065

TOTAL SHAREHOLDERS' EQUITY			214,257	(383)	815,481	(815,098)	214,257
		TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 371,350	$ 120,827	$ 1,134,095	$ (1,231,671)	$ 394,601

Condensed Consolidating Statements of Operations

			Three Months Ended September 30, 2006
			Core		Other
		(In thousands)	Laboratories N.V.	Core	Subsidiaries
			(Parent/	Laboratories L.P.	(Non-	Consolidating	Consolidated
			Guarantor)	(Issuer)	Guarantors)	Adjustments	Total
REVENUES
	Operating revenues		$ -	$ 28,301	$ 117,225	$ -	$ 145,526
	Intercompany revenues		-	3,985	27,983	(31,968)	-
	Earnings from consolidated affiliates		24,266	-	(3)	(24,263)	-
		Total revenues	24,266	32,286	145,205	(56,231)	145,526

OPERATING EXPENSES
	Operating costs		348	17,561	92,600	(9,987)	100,522
	General and administrative expenses		1,042	5,244	11	(47)	6,250
	Depreciation and amortization		5	1,346	3,166	-	4,517
	Other expense (income), net		(1,158)	1,593	21,650	(21,638)	447

OPERATING INCOME			24,029	6,542	27,778	(24,559)	33,790
Interest expense			220	1,701	9	-	1,930

Income before income tax expense			23,809	4,841	27,769	(24,559)	31,860
Income tax expense			1,425	1,875	6,176	-	9,476
NET INCOME			$ 22,384	$ 2,966	$ 21,593	$ (24,559)	$ 22,384

Condensed Consolidating Statements of Operations

			Three Months Ended September 30, 2005
			Core		Other
		(In thousands)	Laboratories N.V.	Core	Subsidiaries
			(Parent/	Laboratories L.P.	(Non-	Consolidating	Consolidated
			Guarantor)	(Issuer)	Guarantors)	Adjustments	Total
REVENUES
	Operating revenues		$ -	$ 20,474	$ 99,710	$ -	$ 120,184
	Intercompany revenues		-	2,222	22,103	(24,325)	-
	Earnings from consolidated affiliates		12,706	-	14,441	(27,147)	-
		Total revenues	12,706	22,696	136,254	(51,472)	120,184

OPERATING EXPENSES
	Operating costs		-	15,232	84,406	(6,874)	92,764
	General and administrative expenses		5,702	5,167	4	-	10,873
	Depreciation and amortization		35	1,910	2,101	-	4,046
	Other expense (income), net		(119)	246	15,670	(17,433)	(1,636)

OPERATING INCOME			7,088	141	34,073	(27,165)	14,137
Interest expense			279	1,610	52	(18)	1,923

Income before income tax expense			6,809	(1,469)	34,021	(27,147)	12,214
Income tax expense (benefit)			(681)	(229)	5,634	-	4,724
NET INCOME			$ 7,490	$ (1,240)	$ 28,387	$ (27,147)	$ 7,490

Condensed Consolidating Statements of Operations

			Nine Months Ended September 30, 2006
			Core		Other
		(In thousands)	Laboratories N.V.	Core	Subsidiaries
			(Parent/	Laboratories L.P.	(Non-	Consolidating	Consolidated
			Guarantor)	(Issuer)	Guarantors)	Adjustments	Total
REVENUES
	Operating revenues		$ -	$ 80,932	$ 341,946	$ -	$ 422,878
	Intercompany revenues		-	10,506	80,925	(91,431)	-
	Earnings from consolidated affiliates		65,845	-	12,849	(78,694)	-
		Total revenues	65,845	91,438	435,720	(170,125)	422,878

OPERATING EXPENSES
	Operating costs		503	50,816	278,689	(29,143)	300,865
	General and administrative expenses		6,145	19,345	15	(47)	25,458
	Depreciation and amortization		21	3,979	8,729	-	12,729
	Other expense (income), net		(1,342)	3,683	56,635	(61,945)	(2,969)

OPERATING INCOME			60,518	13,615	91,652	(78,990)	86,795
Interest expense			612	4,145	28	-	4,785

Income before income tax expense			59,906	9,470	91,624	(78,990)	82,010
Income tax expense (benefit)			2,417	(946)	23,050	-	24,521
NET INCOME			$ 57,489	$ 10,416	$ 68,574	$ (78,990)	$ 57,489

Condensed Consolidating Statements of Operations

			Nine Months Ended September 30, 2005
			Core		Other
		(In thousands)	Laboratories N.V.	Core	Subsidiaries
			(Parent/	Laboratories L.P.	(Non-	Consolidating	Consolidated
			Guarantor)	(Issuer)	Guarantors)	Adjustments	Total
REVENUES
	Operating revenues		$ -	$ 64,460	$ 290,060	$ -	$ 354,520
	Intercompany revenues		-	6,055	64,543	(70,598)	-
	Earnings from consolidated affiliates		32,306	-	35,097	(67,403)	-
		Total revenues	32,306	70,515	389,700	(138,001)	354,520

OPERATING EXPENSES
	Operating costs		-	44,716	248,633	(20,001)	273,348
	General and administrative expenses		7,132	19,037	11	-	26,180
	Depreciation and amortization		105	4,396	7,839	-	12,340
	Other expense (income), net		(1,259)	2,146	47,999	(50,564)	(1,678)

OPERATING INCOME			26,328	220	85,218	(67,436)	44,330
Interest expense			780	5,179	108	(33)	6,034

Income before income tax expense			25,548	(4,959)	85,110	(67,403)	38,296
Income tax expense (benefit)			(914)	(865)	13,613	-	11,834
NET INCOME			$ 26,462	$ (4,094)	$ 71,497	$ (67,403)	$ 26,462

Condensed Consolidating Statements of Cash Flows

			Nine Months Ended September 30, 2006
			Core		Other
		(In thousands)	Laboratories N.V.	Core	Subsidiaries
			(Parent/	Laboratories L.P.	(Non-	Consolidating	Consolidated
			Guarantor)	(Issuer)	Guarantors)	Adjustments	Total

Net cash provided by (used in) operating activities:			$ 83,824	$ (14,895)	$ 11,149	$ -	$ 80,078

CASH FLOWS FROM INVESTING ACTIVITIES:						-
	Capital expenditures		-	(3,092)	(13,255)	-	(16,347)
	Patents and other intangibles		-	(36)	(67)	-	(103)
	Proceeds from sale of assets		-	320	1,902	-	2,222
	Premiums on life insurance		-	(753)	-	-	(753)
Net cash used in investing activities:			-	(3,561)	(11,420)	-	(14,981)

CASH FLOWS FROM FINANCING ACTIVITIES:
	Repayment of debt		(7,339)	(16,100)	-	-	(23,439)
	Proceeds from debt borrowings		8,000	34,000	-	-	42,000
	Capital lease obligations		-	-	(24)	-	(24)
	Stock options exercised		13,859	-	-	-	13,859
	Repurchase of common shares		(104,451)	-	-	-	(104,451)
	Excess tax benefits from stock-based payments		5,671	-	-	-	5,671
Net cash (used in) provided by financing activities:			(84,260)	17,900	(24)	-	(66,384)

NET CHANGE IN CASH AND CASH EQUIVALENTS			(436)	(556)	(295)	-	(1,287)
CASH AND CASH EQUIVALENTS, beginning of period			1,352	(243)	12,634	-	13,743
CASH AND CASH EQUIVALENTS, end of period			$ 916	$ (799)	$ 12,339	$ -	$ 12,456

Condensed Consolidating Statements of Cash Flows

			Nine Months Ended September 30, 2005
			Core		Other
		(In thousands)	Laboratories N.V.	Core	Subsidiaries
			(Parent/	Laboratories L.P.	(Non-	Consolidating	Consolidated
			Guarantor)	(Issuer)	Guarantors)	Adjustments	Total

Net cash provided by (used in) operating activities:			$ 25,836	$ 31,496	$ (1,549)	$ -	$ 55,783

CASH FLOWS FROM INVESTING ACTIVITIES:
	Capital expenditures		-	(12,291)	-	-	(12,291)
	Patents and other intangibles		-	(4)	(99)	-	(103)
	Proceeds from sale of assets		-	1,155	2,267	-	3,422
	Premiums on life insurance		-	-	(475)	-	(475)
Net cash (used in) provided by investing activities:			-	(11,140)	1,693	-	(9,447)

CASH FLOWS FROM FINANCING ACTIVITIES:
	Repayment of debt		(4,035)	(27,661)	(66)	-	(31,762)
	Proceeds from debt borrowings		-	9,000	-	-	9,000
	Debt issuance costs		-	(314)	-	-	(314)
	Capital lease obligations		-	-	(182)	-	(182)
	Stock options exercised		7,012	-	-	-	7,012
	Repurchase of common shares		(27,012)	-	-	-	(27,012)
Net cash used in financing activities:			(24,035)	(18,975)	(248)	-	(43,258)

NET CHANGE IN CASH AND CASH EQUIVALENTS			1,801	1,381	(104)	-	3,078
CASH AND CASH EQUIVALENTS, beginning of period			848	(121)	15,303	-	16,030
CASH AND CASH EQUIVALENTS, end of period			$ 2,649	$ 1,260	$ 15,199	$ -	$ 19,108

Item 6. Exhibits

Exhibit No.		Exhibit Title	Incorporated by reference from the following documents
10.1*		Form of Director Performance Share Award Restricted Share Agreement (ROE Based)	Filed herewith
31.1	-	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
31.2	-	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
32.1	-	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished herewith
32.2	-	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished herewith

	*	Management contract or compensatory plan or arrangement

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant, Core Laboratories N.V., has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			CORE LABORATORIES N.V.
		By:	Core Laboratories International B.V., its
			Managing Director

Dated:	October 26, 2006	By:	/s/ Richard L. Bergmark
			Richard L. Bergmark
			Chief Financial Officer
			Duly Authorized Officer and
			Principal Financial Officer

Certification

Exhibit 31.1

I, David M. Demshur, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Core Laboratories N.V. (the "Registrant");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

	(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):

	(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

	(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date: October 26, 2006	By:	/s/ David M. Demshur
		David M. Demshur
		Chief Executive Officer

Certification

Exhibit 31.2

I, Richard L. Bergmark, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Core Laboratories N.V. (the "Registrant");

	(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

	(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

	(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date: October 26, 2006	By:	/s/ Richard L. Bergmark
		Richard L. Bergmark
		Chief Financial Officer

Exhibit 32.1

Certification of

Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, David M. Demshur, Chief Executive Officer of Core Laboratories N.V. (the "Company"), hereby certify that the accompanying report on Form 10-Q for the quarter ended September 30, 2006, filed by the Company with the Securities and Exchange Commission on the date hereof fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, (the "Report").

I further certify that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 26, 2006	/s/ David M. Demshur
	Name: David M. Demshur
	Title: Chief Executive Officer

Exhibit 32.2

Certification of

Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, Richard L. Bergmark, Chief Financial Officer of Core Laboratories N.V. (the "Company"), hereby certify that the accompanying report on Form 10-Q for the quarter ended September 30, 2006, filed by the Company with the Securities and Exchange Commission on the date hereof fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, (the "Report").

I further certify that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 26, 2006	/s/ Richard L. Bergmark
	Name: Richard L. Bergmark
	Title: Chief Financial Officer